December 22, 2025 AlertsNew BIOSECURE Act Targets Foreign-Linked BiotechBy Jianming Jimmy Hao, Ph.D., Joe Chen, Ph.D., Jonathan R. Lagarenne and Gerard P. Norton, Ph.D.
June 26, 2025 ArticlesHow to Navigate the Biosimilar and Biologic Markets Amid Challenging US Litigation TrendsIntellectual Asset ManagementBy Gerard P. Norton, Jonathan R. Lagarenne, Jianming Jimmy Hao, Howard S. Suh and Jonathan J. Madara
August 25, 2023 ArticlesBiosimilars and Biologics Litigation in the United StatesIAMBy Gerard P. Norton, Ph.D., Jonathan R. Lagarenne, Jianming Jimmy Hao, Ph.D., Howard S. Suh and Jonathan J. Madara
May 18, 2023 AlertsSupreme Court Unanimously Affirms Enablement Requirement in Closely Watched Amgen-Sanofi CaseBy Jonathan Madara*, Jianming Jimmy Hao, Peter F. Corless and Gerard P. Norton
September 18, 2017 ArticlesSupreme Court's 'Sandoz v. Amgen' Decision Favors BiosimilarsNew Jersey Law JournalBy Gerard P. Norton, Ph.D.
March 27, 2017 ArticlesFDA Issues New Draft Guidance on BiosimilarsThe National Law JournalBy Gerard P. Norton, Ph.D.
January 08, 2016 ArticlesThe Trans-Pacific Partnership Patent Provisions’ Impact on the U.S. Pharmaceutical IndustryBloomberg BNABy Gerard P. Norton, Ph.D.